Soligenix, Inc. (SNGX)

Soligenix's stock price has declined significantly over the past six months, with a 46.19% decrease from March 27, 2025, to March 25, 2026, and a 50.63% decrease over the last year. A reverse stock split with a ratio of 1:16 occurred on June 6, 2024. Key factors impacting the stock price include persistent financial losses, with a net loss of $11.1 million reported for 2025, and no revenues for 2025. Shareholder dilution has also been a factor. Upcoming milestones include an interim analysis in Q2 2026 and top-line results in H2 2026 from the Phase 3 FLASH2 trial of HyBryte™, as well as positive regulatory designations for SGX945 in Europe and the UK in March 2026.

Soligenix, Inc. (SNGX) exhibits distinct seasonal tendencies in its stock performance based on 27 years of historical data. January has been the strongest month, with an average return of 30.37%, while October tends to be the weakest month, averaging a -10.36% return. The overall average annual return for SNGX is 8.80%. This seasonality primarily reflects investor demand for the stock rather than direct demand for the company's products and services.

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs, operating in the Healthcare sector, specifically in Pharmaceutical Preparation Manufacturing, and categorized under the Biotechnology industry. The company's business is divided into Specialized BioTherapeutics and Public Health Solutions. Key products include HyBryte™ (SGX301) for cutaneous T-cell lymphoma, SGX302 for psoriasis, SGX942 (dusquetide) for inflammatory diseases, SGX945 (dusquetide) for aphthous ulcers in Behçet's Disease, RiVax® as a ricin toxin vaccine candidate, CiVax™ as a vaccine candidate for COVID-19 prevention, and ThermoVax®, a heat stabilization platform technology used in its vaccine programs.

Soligenix, Inc. is headquartered in Princeton, New Jersey, United States, with a primary focus on product development and commercialization in the United States. Regulatory designations in Europe and the UK for products like HyBryte™ and SGX945 indicate international aspirations and presence in these markets.

Soligenix's brand reputation has been positively influenced by regulatory achievements for its pipeline products, including Orphan Drug and Fast Track designations from the FDA for HyBryte™, and Orphan Drug Designation from the FDA and the European Commission for SGX945. Persistent financial losses and stock price decline could implicitly affect investor confidence and perception.

The ownership structure of Soligenix (SNGX) includes institutional investors (1.61% to 3.60%), insiders (around 3.86%), and the general public and individual investors (72.51% to 93.31%). Major institutional shareholders include DRW Securities, LLC, Vanguard Group Inc, and Geode Capital Management, Llc. Robert J. Rubin owns the most shares among individual investors.